Skip to main content
$172.94 $0.86 (0.5%)

04:00 PM EDT on 10/15/21

Acceleron Pharma (NASDAQ:XLRN)

CAPS Rating: 2 out of 5

Current Price $172.94 Mkt Cap $10.6B
Open $172.93 P/E Ratio 0.00
Prev. Close $172.94 Div. (Yield) $0.00 (0.0%)
Daily Range $171.91 - $173.55 Volume 408,525
52-Wk Range $99.98 - $189.99 Avg. Daily Vol. 1,169,230

Caps

How do you think NASDAQ:XLRN will perform against the market?

Add Stock to CAPS Watchlist

All Players

35 Outperform
4 Underperform
 

All-Star Players

9 Outperform
0 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:XLRN Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

TMFSpiffyPop (99.89)
Submitted June 29, 2015

Bit of a flyer, but I like orphan-drug companies and in this case the partner is Celgene, a company I greatly esteem. Outperform.

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NASDAQ:XLRN VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about XLRN.

Recs

0
Member Avatar TMFEBCapital (96.80) Submitted: 11/20/2018 11:10:00 AM : Outperform Start Price: $50.39 NASDAQ:XLRN Score: +175.88

Potential for short-term catalyst at ASH in December, longer term catalyst approval of luspatercept for beta thalassemia and MDS. Luspatercept's licensed to the best partner in bone marrow disorders, Celgene, and Celgene owns over 12% of XLRN already. $2 billion peak sales potential for luspatercept suggests XLRN arguably undervalued.

Recs

0
Member Avatar Bigsef77 (69.82) Submitted: 6/29/2018 10:14:54 AM : Outperform Start Price: $28.56 NASDAQ:XLRN Score: +419.94

Celgene and Acceleron Announce Luspatercept Achieved Primary and Key Secondary Endpoints in Phase III ‘MEDALIST’ Study in Patients with Low-to-Intermediate Risk Myelodysplastic Syndromes

Recs

0
Member Avatar mdriver78 (75.36) Submitted: 7/27/2015 9:04:17 AM : Outperform Start Price: $28.59 NASDAQ:XLRN Score: +390.22

SpiffyPop

Leaderboard

Find the members with the highest scoring picks in XLRN.

Score Leader

K28hill

K28hill (20.23) Score: +571.64

The Score Leader is the player with the highest score across all their picks in XLRN.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
K28hill 20.23 9/24/2013 Outperform 5Y $20.78 +733.30% +161.66% +571.64 0 Comment
DoubleBagel 35.62 1/23/2017 Outperform 5Y $24.24 +614.36% +97.37% +516.99 0 Comment
stockpickeraz 25.94 9/25/2013 Outperform 3W $22.20 +680.00% +163.34% +516.66 0 Comment
Hoofer38 57.45 10/23/2013 Outperform 5Y $23.33 +642.22% +155.39% +486.83 0 Comment
ReaperKK < 20 9/3/2014 Outperform 3Y $26.58 +551.47% +121.30% +430.17 1 Comment
Bigsef77 69.82 5/11/2017 5/6/2021 Outperform 5Y $28.56 +506.30% +86.36% +419.94 1 Comment
mdriver78 75.36 7/27/2015 8/3/2020 Outperform 5Y $28.59 +505.67% +115.45% +390.22 1 Comment
TheLusciousLucas 92.46 8/26/2014 Outperform NS $28.53 +507.05% +122.32% +384.73 0 Comment
portefeuille 98.70 5/4/2015 5/31/2021 Outperform NS $29.57 +485.69% +110.98% +374.71 0 Comment
wmtworker 80.52 7/6/2015 Outperform 5Y $29.52 +486.59% +116.58% +370.01 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for XLRN.